Protecting Kids from Pneumonia Washington DC

The current recommended dose schedule for 7-valent pneumococcal conjugate vaccine (PCV-7) consists of three primary doses before the age of 6 months, followed by a booster vaccination in the second year of life (3 + 1-dose schedule) in Washington.

Ruth Ellen Scrano, MD
(202) 734-2687
1811 8th St NW # 2
Washington, DC
Specialties
Pediatrics
Gender
Female
Education
Medical School: Univ Of Mi Med Sch, Ann Arbor Mi 48109
Graduation Year: 2000

Data Provided by:
Burman Kenneth MD
(202) 877-6563
Washington Hospital
Washington, DC
 
Rainford Monique MD
(202) 877-6054
Washington Hospital
Washington, DC
 
Panza Julio MD
(202) 877-3109
Washington Hospital
Washington, DC
 
Shafkat Anwar, MD
Apt B 61 Rhode Island Ave NW
Washington, DC
Specialties
Pediatrics
Gender
Male
Education
Graduation Year: 2005

Data Provided by:
Patel Ketan H MD
(202) 776-0575
1116 21st
Washington, DC
 
Veis Judith MD
(202) 877-6034
Washington Hospital
Washington, DC
 
Jelinek James MD
(202) 877-6550
Washington Hospital
Washington, DC
 
Colice Gene MD
(202) 877-0218
Washington Hospital
Washington, DC
 
Tseng Daniel MD
(202) 877-3109
Washington Hospital
Washington, DC
 
Data Provided by:

Protecting Kids from Pneumonia

Provided By:

Parents and babies alike will be relieved by new findings that show a reduced-dose schedule for the pneumococcal vaccine can protect infants against pneumonia and other infections.

The current recommended dose schedule for 7-valent pneumococcal conjugate vaccine (PCV-7) consists of three primary doses before the age of 6 months, followed by a booster vaccination in the second year of life (3 + 1-dose schedule). But factors such as questions about the cost-effectiveness of the current PCV-7 dose schedule have led researchers to examine reduced-dose vaccine schedules, according to background information in the study.

The researchers, Dr. Elske J.M. van Gils, of the University Medical Center Utrecht in the Netherlands, and colleagues, studied 1,003 healthy infants who were randomly assigned to receive two doses of PCV-7 at 2 months and 4 months of age, or a 2 + 1-dose schedule at 2, 4 and 11 months of age, or no vaccine (control group). The children were checked after 12 months, 18 months and 24 months for pneumococcal microorganisms in the upper part of the throat behind the nose.

Compared to those in the control group, children in both vaccine groups had far lower rates of microorganisms that can cause pneumonia and other infections, according to the report in the July 8 issue of the Journal of the American Medical Association.

"In conclusion, both two-dose and 2 + 1-dose schedules of PCV-7 significantly reduce vaccine serotype pneumococcal carriage in children. This study supports future implementation of reduced-dose PCV-7 schedules," the researchers concluded.

More information

The Nemours Foundation has more about children and pneumonia.

SOURCE: Journal of the American Medical Association, news release, July 7, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com